CN101828707A - Nutrition composition and application thereof - Google Patents
Nutrition composition and application thereof Download PDFInfo
- Publication number
- CN101828707A CN101828707A CN200910047331A CN200910047331A CN101828707A CN 101828707 A CN101828707 A CN 101828707A CN 200910047331 A CN200910047331 A CN 200910047331A CN 200910047331 A CN200910047331 A CN 200910047331A CN 101828707 A CN101828707 A CN 101828707A
- Authority
- CN
- China
- Prior art keywords
- calcium
- alimentation composition
- vitamin
- preparation
- acid
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Pending
Links
Landscapes
- Coloring Foods And Improving Nutritive Qualities (AREA)
- Medicinal Preparation (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
Abstract
The invention discloses a nutrition composition and application thereof. The nutrition composition comprises the following active ingredients in percentage by weight: 5-94.7 percent of calcium, 0.0001-0.02 percent of vitamin k, 5-94.7 percent of oil and 0.01-0.4 percent of antioxidant. The nutrition composition greatly enhances the bioavailability of the calcium, has multiple health care functions, and has obvious functions on controlling cancers, cardiac, cerebral and vascular diseases, diabetes, rheumatic disease, dermatitis, depression, dementia praecox, Alzheimer's disease, allergy, asthma, nephropathy, senium and chronic obstructive pulmonary disease, enhancing intelligence and immunity, protecting eyesight, promoting skeleton growth and preventing osteoporosis, thereby being suitable for being taken by various people and being a difunctional product which has the function of calcium and memory simultaneous supplement and can satisfy the need by the development of infant body and brain.
Description
Technical field
The invention belongs to food technology field, be specifically related to a kind of calcium alimentation composition and uses thereof.
Background technology
The healthy of diet structure and people is closely-related.Keep fit except absorbing compositions such as enough protein, fat, also need comprehensively, balancedly absorb various vitamins and mineral matter.Therefore, can develop targetedly that to meet nutrition and medical requirement, the health food of the nutrition of needed by human body is provided be to be necessary very much and wide market prospects are arranged.
Calcium is one of necessary macroelement of human body, especially for the infant on the peak of growing, the extra effect that replenishes calcium is extremely important, can not only guarantee the infant skeleton development, drive other normal physiological function, can also prevent old osteoporosis.
Owing to reasons such as diet structures, the calcium deficiency phenomenon is very serious.The existing product category of replenishing the calcium is also more.Usually, these products of replenishing the calcium are to add the calcium composition in food, as health foods such as the calcium activated that occurs on the market, bone-strengthening powders.But most of calcium supplement health care food are only paid attention to the content of calcium in the product, do not pay attention to the biological utilisation degree of human body to calcium, and failure causes replenishing the calcium.Simultaneously, existing calcium supplement health care food also exists the defective that effect is single, can't satisfy the many-sided needs of people.
Summary of the invention
Technical problem to be solved by this invention is to disclose a kind of alimentation composition and uses thereof, and the bioavilability that prior art exists is low to overcome, the defective of function singleness.
Alimentation composition of the present invention comprises the active component of following percentage by weight:
Calcium agent 5～94.7%
Vitamin k 0.0001～0.02%
Grease 5～94.7%
Antioxidant 0.001～0.4%
Each percentages of ingredients sum is 100%;
Preferably:
Calcium agent 11.8～88%
Vitamin k 0.0002～0.02%
Grease 11.8～88%
Antioxidant 0.006～0.3%
Each percentages of ingredients sum is 100%;
Described calcium agent is selected from more than one in milk calcium, calcium carbonate, calcium gluconae, amino acid acid chelating calcium, calcium phosphate, calcium chloride, calcium lactate, L-calcium lactate, calcium citrate, citric acid-calcium malate, hydroxyl calcium phosphate, calcium acetate or the l threonic acid, preferred milk calcium, calcium citrate, calcium phosphate, calcium chloride, calcium carbonate or calcium lactate;
Described milk calcium has another name called whey calcium, it is the organic calcium source, milk calcium is whey inorganic salts concentrates, be the best inorganic Yanyuan of nutritive value and easily digest and assimilate, be the high lactoprotein calcium of pure natural active that directly from milk, extracts, except good absorbing, calcium phosphorus ration 2: 1, also contain trace element and mineral matter that other calcium sources are not contained, especially be fit to infants, can adopt the commercially available prod, the commercially available prod comprises: the Trucal brand of U.S. Ge Lanbiya (import of Shanghai Ai Lanbiya International Trading Company Ltd); New Zealand Dairy Company NZMP brand; My raw-food material company of Denmark
Brand; Dai Weilin agency's Dutch Dmv brand; It can also be the milk calcium that Dutch Fiesland Foods Domo Fei Shilan food or New Zealand Na Ruisi enterprise produce.The Trucal brand of preferred U.S. Ge Lanbiya (Ai Lanbiya).
Described vitamin k is selected from the derivative of vitamin K1, farnoquinone, farnoquinone or contains the food of described vitamin K, as the freeze dry powder of fermented soybean or the natto extract of Pei Baokang Industry Co.,Ltd;
Vitamin K is divided into two big classes, and a class is a liposoluble vitamin, the synthetic farnoquinone of vitamin K1 that promptly from green plants, extracts and enteric bacteria (as Escherichia coli), and another kind of is water miscible vitamin, is prokeyvit and K4 by manually synthesizing.Vitamin K mainly participates in regulating blood clotting and sclerotin metabolism.
Infant period, normal flora is imperfect as yet in the enteron aisle, and enteric bacteria synthetic vitamin K lacks, if during pregnant female vitamin K deficiency, vitamin K deficiency takes place easily then.Therefore, for the infant, replenishing vitamins K is particularly necessary.
Described MK7 is a kind of of farnoquinone, it is the coenzyme of glutamic acid gamma-carboxylase, can participate in the γ position carboxylated of glutamic acid in the BGP, thereby calcareous deposition in the increase bone, increase bone density, can also suppress bone and absorb, reduce calcium loss, also have prevention canceration, prevention and reverse angiosteosis simultaneously, improve bone density and improve physiological action such as osteoproliferation.
Described grease is the grease that is rich in alpha-linolenic acid, be rich in the algal oil of DHA or be rich in the fish oil of DHA, row as: dogfish oil, shark oil, cod oil, cod-liver oil, tunny fish oil, tuna liver oil etc.;
The described grease that is rich in alpha-linolenic acid includes but not limited in Purple Perilla Seed Oil, linseed oil (or being called siritch), silkworm chrysalis oil or the Chinese prickly ash seed oil more than one, preferred linseed oil.
In linseed oil active ingredient, alpha-linolenic acid accounts for 40-50%.Alpha-linolenic acid belongs to ω-3 series (or n-3 series) aliphatic acid, after it enters human body, under the catalysis of enzyme (dehydrogenase and carbochain prolong enzyme), can change into EPA (Eicosa Pentaenoic Acid, EPA, eicosapentaenoic acid) and DHA (Docosa Hexaenoic Acid, DHA, DHA).Alpha-linolenic acid, EPA and DHA are referred to as ω-3 series (or n-3 series) aliphatic acid, and alpha-linolenic acid is precursor or parent, and EPA and DHA are the back body or the derivative of alpha-linolenic acid.DHA and EPA play a part very important to the g and D of the division of brain nervous cell, propagation, nerve conduction, cynapse, be the essential material that brain forms and IQ is developed.Linseed oil relatively directly adds DHA, more stablely is not easy oxidation, and is also safer from the angle of biological chain and food security, reduces effectively that the deep-sea is polluted and danger such as hormone residues.Simultaneously, alpha-linolenic acid is of value to prevention and treatment cancer, cardiovascular and cerebrovascular diseases, diabetes, rheumatoid disease, dermatitis disease, depression, schizophrenia, senile dementia, allergy, asthma, ephrosis, human senility and chronic plug pneumonia etc. and increases intelligence, strengthens immunity, vision protection.In a single day human body lacks alpha-linolenic acid, will cause the human body disorders of lipid metabolism, causes the generation of symptoms such as immunity reduces, forgetful, tired, hypopsia, atherosclerotic.Especially infant, teenager if lack alpha-linolenic acid, will have a strong impact on the growth of its intelligence and eyesight; When alpha-linolenic acid and milk calcium use simultaneously, the synergy that promotes that calcium absorbs is arranged.
Described antioxidant is selected from a kind of in Tea Polyphenols, flavones, ellagic acid, vitamin E, vitamin C, sodium pyrosulfite or the dibutyl hydroxy toluene;
The invention still further relates to a kind of preparation that contains described alimentation composition, described preparation comprise pharmaceutically described or food on acceptable carrier;
Preferably, in the preparation, the weight content of described alimentation composition is 15%～90%
Described carrier comprises excipient, adhesive, filler, diluent, tablet agent, lubricant, disintegrant, colouring agent, flavor enhancement and wetting agent etc., can carry out dressing to tablet;
The filler that is suitable for comprises cellulose, mannitol, lactose and other similar filler.
Suitable disintegrant comprises that starch, polyethylene adjoin pyrrolidone and starch derivatives, for example sodium starch glycollate.
Suitable lubricant comprises dolomol.
Suitable wetting agent comprises lauryl sodium sulfate.
Can be by means commonly known in the art, preparation becomes any oral liquid formulation or solid pharmaceutical preparation, and these formulations comprise: tablet, sugar coated tablet, film coated tablet, enteric coated tablet, capsule, hard capsule, soft capsule, oral liquid, syrup, suck agent, granule, electuary, pill, powder, paste, sublimed preparation, supensoid agent, solution, suppository, ointment, emplastrum, creme, spray, patch, sustained release preparation or controlled release preparation;
Described preparation, can contain conventional additive, such as suspending agent, for example sorbierite, syrup, methylcellulose, gelatin, hydroxyethylcellulose, carbonyl methyl cellulose, aluminium stearate gel or hydrogenation edible fat, emulsifying agent, for example lecithin, anhydro sorbitol-oleic acid vinegar or Arabic gum; Non-aqueous carrier (they can comprise edible oil), for example apricot kernel oil, fractionated coconut oil, such as glyceride, propane diols or ethanol; Anticorrisive agent, for example para hydroxybenzene methyl esters or propylparaben or sorbic acid, and if desired, can contain conventional flavouring agent or and colouring agent.
Animal experiment proves, alimentation composition of the present invention, described alimentation composition is in prevention or treatment cancer, cardiovascular and cerebrovascular diseases, diabetes, rheumatoid disease, dermatitis disease, depression, schizophrenia, senile dementia, allergy, asthma, ephrosis, aging and chronic plug pneumonia and increase intelligence, strengthen immunity, vision protection, promotion skeleton development, prevent aspect the osteoporosis significant effect is arranged;
The effective dose of used alimentation composition can change with the order of severity of mode of administration and disease to be treated.Yet, when alimentation composition of the present invention every day gives with the dosage of about 5～100mg/kgbw, can obtain gratifying effect usually, preferably give with the dosage that separates for 2-4 time every day, or with the slowly-releasing form administration.For most of large mammal, the accumulated dose of every day is about 100-4000mg.Can regulate this therapeutic scheme to reach optimum therapeuticing effect.For example, can be according to the needs of situation, every day, several times were separately taken, or dosage is reduced in proportion.Usually, the scope of adult's oral dose is 1000-4000mg/ day, is preferably 1500-3000mg/ day, and the scope of infant's oral dose is 10-3000mg/ day, is preferably 500-1500mg/ day.
Animal experiment proves simultaneously, alimentation composition of the present invention, and avirulence is taken for a long time, no habituation.
Alimentation composition disclosed in this invention; the bioavilability that has solved existing calcium supplement health care food effectively is low; the problem of function singleness; the vitamin k that promotes the calcium absorption function is arranged by adding; improved the bioavailability of calcium greatly; the adding of linseed oil has the synergy that extremely strong promotion calcium absorbs; this alimentation composition possesses plurality of health care functions simultaneously; in prevention and treatment cancer; cardiovascular and cerebrovascular diseases; diabetes; rheumatoid disease; dermatitis disease; depression; schizophrenia; senile dementia; irritated; asthma; ephrosis; old and feeble and chronic plug pneumonia and increasing intelligence; strengthen immunity; vision protection; promote skeleton development; prevent that the osteoporosis aspect has tangible effect; it is edible to be fit to various crowds; especially infant and adult female; mend together for a kind of calcium brain, can satisfy the difunctional product of infant's health and brain development needs.
The specific embodiment
Below in conjunction with specific embodiment, further illustrate the present invention.Should be understood that these embodiment only to be used to the present invention is described and be not used in and limit the scope of the invention.The experimental technique of unreceipted actual conditions in the following example, usually according to normal condition, or the condition of advising according to manufacturer.Ratio and percentage are based on weight, unless stated otherwise.
The embodiment of the invention is raw materials used be commercially available.
Embodiment 1. alimentation composition capsule and pills
Prescription: 1000mg/ grain (about 5000)
| Composition | Recipe quantity (mg/ grain) |
| Milk calcium | ??99.9 |
| Linseed oil | ??797.22 |
| Farnoquinone | ??0.18 |
| Soybean lecithin | ??10 |
| Soya-bean oil | ??90 |
| ??VE | ??2.7 |
Above composition mixed make finish.
Milk calcium adopts the Trucal brand of U.S. Ge Lanbiya (import of Shanghai Ai Lanbiya International Trading Company Ltd);
2400g gelatin (40%), 2400g glycerine (40%) and 1200g pure water (20%) were mixed 2 hours at 80 ℃, obtain colloidal sol, above-mentioned then finish and colloidal sol mixing pelleting, rubber thickness: 0.80mm ± 0.05mm, finalized the design 4 hours, alcohol is washed ball, drying: the primary drying temperature: 28 ℃, humidity 15%, time 4h; The redrying temperature: 32 ℃, humidity 15%, 4h; Rubber moisture: 13%, alcohol is washed ball then, obtains capsule and pill.
Embodiment 2. alimentation composition capsule and pills
Prescription: 1000mg/ grain
| Composition | Recipe quantity (mg/ grain) |
| Milk calcium | ??797.22 |
| Linseed oil | ??99.9 |
| Farnoquinone | ??0.002 |
| Soybean lecithin | ??17 |
| Soya-bean oil | ??80 |
| ??VE | ??2.878 |
The preparation method is with embodiment 1.
Embodiment 3. alimentation composition capsule and pills
Prescription: 1000mg/ grain
| Composition | Recipe quantity (mg/ grain) |
| Calcium citrate | ??420 |
| Linseed oil | ??417 |
| ??MK7 | ??0.1 |
| Soybean lecithin | ??10 |
| Soya-bean oil | ??150 |
| ??VE | ??2.9 |
The preparation method is with embodiment 1.
Embodiment 4. alimentation composition tablets
Utilize routine techniques, mix following component, direct tablet compressing then, the pharmaceutical composition of preparation tablet form, its prescription is as follows:
| Composition | Recipe quantity (mg/ sheet) |
| Calcium citrate | ??90 |
| Silkworm chrysalis oil | ??60 |
| ??MK7 | ??0.02 |
| Tea Polyphenols | ??0.01 |
| Microcrystalline cellulose | ??40 |
| Cornstarch | ??6 |
| Sodium carboxymethyl starch | ??3 |
| Dolomol | ??1 |
The influence that embodiment 5. alimentation compositions stay in the storage of rat skeletal calcium
1 materials and methods
1.1 material
Calcium carbonate (AR level, Ca content 40%), milk calcium (AR level, Ca content 24%).
1.2 animal grouping
Select ablactation 70 of rats of Wistar (Shenyang Pharmaceutical University zoopery center provides) just for use, between the body weight 80-100g, be divided into 7 groups at random, 10 every group.The background group is all put to death before the experiment beginning, surveys bilateral femur weight, length and femur calcium content.All the other 6 groups are divided at random by body weight: 2. group is organized, tested to experiment contrast group, calcium carbonate group, milk calcium group, milk calcium+VK2 group, experiment 1..
1.3 animal feeding
The experiment contrast group is fed low calcium basal feed (with reference to the AOAC prescription), and calcium content is 0.01%; Calcium alimentation composition calcium content is 2.3976% among the embodiment 1, this alimentation composition and low calcium basal feed is mixed than row according to 20.92% and 79.08% to obtain final ca content be 0.5% mixture, is called " 1. experiment is organized "; Calcium alimentation composition calcium content is 19.13% among the embodiment 2, this alimentation composition and low calcium basal feed is mixed than row according to 2.61% and 97.38% to obtain final ca content be 0.5% mixture, is called " 2. experiment is organized "; Other are respectively organized feed formula and see Table 1, and each experimental group is added a certain amount of calcium carbonate respectively on low calcium feed basis, milk calcium, and VK2 makes that final ca content is 0.5%.
The single cage of experimental session animal is fed, and drinks deionized water, and ad lib writes down food-intake day by day, and experiment periods is 28d.Put to death whole rats at last, get the both sides femur, weigh, survey length, survey calcium content.
1.4 mensuration content and method
1.4.1 femur weight and length
Slide measure (Shanghai measurer factory, precision is 0.02mm) is measured femur length.MP120-1 type electronic balance (Shanghai Second Balance Factory, sensitivity is 1mg) weighs femur weight.
1.4.2 calcium content
Feed calcium and femur calcium are all after the ashing of muffle furnace high temperature, with PE-2380 type atomic absorption spectrophotometer.
1.4.3 data are handled
Rate=(the test back femur calcium-preceding femur calcium of test)/always take in calcium * 100% is stayed in femur calcium storage;
Femur index=bilateral femur weight/body weight; Relatively adopt the t check between each group.
Table 1 feed formula (g/100g)
2 results and conclusion
Femur parameters and femur calcium that table 2, table 3 are observed rat respectively retain: experiment contrast group femur index is 4.43, and it is 2.27% that rate is stayed in the storage of femur calcium; Calcium carbonate group femur index is 5.06, and the femur calcium rate of retaining is 3.96%; Milk calcium group femur index is 5.28, and the femur calcium rate of retaining is 4.48%; Milk calcium+VK2 group femur index is 5.48, and the femur calcium rate of retaining is 4.68%; 1. experiment organizes the femur index is 5.88, and the femur calcium rate of retaining is 6.25%; 2. experiment organizes the femur index is 5.81, and the femur calcium rate of retaining is 5.83%.
Each experimental group is under the situation that total calcium intake equates, the milk calcium+VK2 group result of use of adding VK2 is better than milk calcium group and calcium carbonate group; 1. the experiment of having added linseed oil is organized, is tested and 2. organize result of use significantly better than the milk calcium that does not add linseed oil+VK2 group; 1. the experiment that linseed oil content is high organizes that 2. to organize result of use better than experiment.Above-mentioned experimental result shows: VK2 can promote the absorption of calcium greatly; Linseed oil has the collaborative effect that promotes that calcium absorbs, and can well improve utilization rate and the storage rate of calcium in bone.The effect of all helpful bone utilization of calcium alimentation composition in deducibility " embodiment 1 " and " embodiment 2 " and storage calcium can be used as the good calcium source of body.
The relevant physical property of table 2 femur (n=10)
(compare with the experiment contrast group * P＜0.01; Compare with other group in △ P＜0.05).
Table 3 femur calcium content (n=10)
(compare with the experiment contrast group * P＜0.01; Compare with other group △ P＜0.05)
The calcium content (%) of total calcium intake (mg)=feed intake (mg) * feed
Embodiment 6, and the calcium alimentation composition is to pregnant woman and infant intelligent development and calcium level influence
1 data and method
1.1 research object
1.1.1 select pregnant woman's standard
(1) age 20-35 year, the Shenyang urban registered permanent residence, single pregnancy.(2) no bad pregnant history and BH, this gestation is no abnormal, no placental insufficiency.No pregnancy period contact radioactive ray, chemical toxicant and harmful pharmacohistory.(3) no obstetric forceps and fetal head attract to help childbirth.Be divided at random: 1. experiment organizes 80 examples, gives the calcium alimentation composition of embodiment 1 every day to dividing 3 months puerperiums when pregnant 15～18 weeks; 2. experiment organizes 80 examples, gives the calcium alimentation composition of embodiment 2 every day to dividing 3 months puerperiums when pregnant 15～18 weeks.Control group 80 examples are used full diet.
1.1.2 select the fetus standard
(1) 35～41 weeks of gestational age, birth weight 2500-4000g; Apgar scoring in (2) 1 minutes 〉=8 minutes; (3) do not have when producing and infect no congenital heredity metabolic disease.Hospital meets the 240 routine normal pregnancies of choice criteria and the mature healthy newborn of childbirth thereof, pregnant woman age 20～35 years old, average 26 years old, 35～40 weeks of gestation, birth weight 2550～3850g, average 3302g, the male sex's 120 examples (50%) wherein, women's 120 examples (50%) are cutd open the palace and are produced 96 examples (40%), vaginal delivery 144 examples (60%) are accepted 0～3 years old infant's intellectual development scale and are checked 240 examples.The male sex's 120 examples (50%) wherein, women's 120 examples (50%).
1.2 research method
1.2.1 sample collection and DHA measure
Respectively at gestation (20 ± 2) week, (32 ± 2) week and 37 weeks give a birth preceding and divide and get mother's venous blood and each 4m of umbilical cord venous blood in 4 weeks of puerperium], centrifuging and taking serum, freezing standby.With capillary gas chromatography serum DHA total amount.Sample is used inner mark method ration after formicesterization, DHA formicester standard items are U.S. SIGMA company product, and other reagent is that homemade analysis is pure.
1.2.2 infant intelligence test
Adopt 0～3 years old infant's intellectual development scale (CDCC), the baby in 3～4 months postpartum is detected spiritual developmental index (MDI) and motor development index (PDI).Check that environmental requirement is quiet, warm, the light foot.The baby carries out under waking state.Evaluation criteria is: 〉=120 are divided into outstandingly, and 80～119 are divided into normally, and 70～79 are divided into suspicious feeblemindedness, and≤69 are divided into feeblemindedness.
Fixedly the inspector is served as by the qualified high age and service seniority pediatrician of training, adopts double-blind study to check.
1.2.3 pregnant woman and baby's blood calcium concentration are measured
Gather (28 ± 2) all pregnant woman's venous blood, neonate's bleeding of the umbilicus, adopt serum total calcium content in the semi-automatic biochemical analyzer working sample.
1.3 data are handled and statistical method
Check data, coding input computer adopts SPSS 14.0 statistical softwares to carry out data and handles.Statistics
Method: test of normality, F check.
2 experimental results:
2.1 alimentation composition is to female blood, bleeding of the umbilicus DHA level affects (mg/l) (seeing Table 4)
2.2 the calcium alimentation composition is to infant intelligent development influence (seeing Table 5)
2.3 the calcium alimentation composition is to pregnant woman and the total calcium influence of neonate's serum (mmol/L) (seeing Table 6)
Table 4 alimentation composition is to female blood, bleeding of the umbilicus DHA level affects (mg/L)
Table 5 calcium alimentation composition influences infant intelligent development
Table 6 calcium alimentation composition is to pregnant woman and the total calcium influence of neonate's serum (mmol/L)
3 experiment conclusion
(1) 2. 1. experiment organize and test in the serum of group the DHA contents level apparently higher than control group, show that pregnant woman is rich in the linolenic calcium alimentation composition of Alpha, efficiently be converted into DHA by the enzyme system metabolizable energy in vivo, help to improve pregnant woman's nutrition condition, also help DHA to shift to fetus simultaneously from parent.
(2) 2. 1. experiment organize and test baby's spirit developmental index of group and exercise index apparently higher than control group, illustrates that the calcium alimentation composition plays special role to infant's brain development.
(3) pregnant woman and infant's blood calcium determination result: 26 examples are arranged in the experiment contrast group, account for 32.5% pregnant woman and the total calcium concentration of neonate's serum and be lower than normal value (2.25～2.75mmol/L), clinical manifestation is a calcium deficiency; 1. the experiment of the alimentation composition of edible embodiment 1 and embodiment 2 is organized and is tested 2. to organize and compare with control group, and effect is remarkable, and all are tried the pregnant woman and infant's serum total calcium concentration value is all normal.Result of the test shows that the calcium alimentation composition is obvious to pregnant woman and infant's effect of supplemented calcium.
Embodiment 7, and the calcium alimentation composition improves the animal experiment study of memory effect
1. materials and methods
1.1 experimental animal grouping
Select ablactation 50 of rats of Wistar (Shenyang Pharmaceutical University zoopery center provides) just for use, between body weight 80～100g, be divided into 5 groups at random, 10 every group.
1.2 tried thing and dosage
The experiment contrast group basal feed (Shenyang Pharmaceutical University zoopery center provides) of feeding; 1. experiment is organized, is tested 2. to organize and irritate the calcium alimentation composition that stomach gives 0.4g/kgbw and 1.2g/kgbw embodiment 1 respectively on the basal feed basis of feeding; 3. experiment is organized, is tested 4. to organize and irritate the calcium alimentation composition that stomach gives 0.4g/kgbw and 1.2g/kgbw embodiment 3 respectively on the basal feed basis of feeding.
1.3 instrument
The diving tower instrument, keep away dark instrument and water maze instrument (institute of Materia Medica,Chinese Academy of Medical Sciences production).
1.4 method
1.4.1 diving tower experiment
Select ablactation 50 of rats of Wistar (Shenyang Pharmaceutical University zoopery center provides) just for use, between the body weight 80-100g, be divided into the blank group at random, test and 1. organize, test 2. and organize, test 3. and organize, test 4. group, 10 every group.Experimental group is irritated stomach and tried thing every day, carries out the diving tower training after giving sample 30d continuously.Animal is put into reaction chamber endoadaptation 4min, pass to 36 volts of alternating currents immediately, the normal reaction of animal is to jump back on the insulated platform.Most animals may be once more or is repeatedly skipped on the copper grid, is subjected to the platform that snaps back again that shocks by electricity.After the training once, animal is placed on the platform in the reaction chamber, every number of times (errors number) that mouse is shocked by electricity in the record 5min, with this as school grade.Resurvey behind the 24h and test, the number of animals that record is shocked by electricity, the incubation period of jumping off platform for the first time and the errors number in the 3min.
1.4.2 keep away dark experiment
Keep away dark experimental animal and select, all same step down test of dosage, approach, time that is tried thing is given in the test grouping, begins to keep away dark training to behind the sample 30d continuously.During experiment the mouse face is put into bright chamber in the hole dorsad, start timer simultaneously, animal passes the hole and enters the darkroom and shocked by electricity, and timer stops, and takes out mouse, writes down every mouse and suffers required time of electric shock, i.e. incubation period from putting into bright chamber to entering the darkroom.The same time behind the 24h, carry out cyclical test, write down incubation period, the errors number in the 5min and the number of animals that enters the darkroom that every mouse enters the darkroom.
1.4.3 water maze test
The water maze test animal is selected, and all same step down test of dosage, approach, time that is tried thing is given in the test grouping, begins to keep away dark training to behind the sample 30d continuously.Training period continues to being tried thing, every day 1 time.Labyrinth swimming lane depth of water 15cm, water temperature (25+1) ℃.During experiment, mouse is put in the starting point place of swimming lane, picks up counting, observe its required time of reaching home, and errors number occurs.The mouse training time is defined as 120s, and the mouse of no show terminal point all is designated as 120s in 120s.Train 5d altogether, last is trained from starting point.At last estimate (time of promptly respectively organizing the number of animals of reaching home in two minutes, every group of 5d average error number of times and reaching home) with total school grade of 5d.
1.4.4 data are handled
Gained data The data SPSS 14.0 statistical packages carry out statistical disposition, and statistical method adopts variance analysis and X
2Check.The results are shown in Table 7, table 8 and table 9.
The influence (diving tower method) that table 7 calcium alimentation composition obtains mouse memory
The influence (darkness avoidance test) that table 8 calcium alimentation composition obtains mouse memory
The influence (water maze) (5 overall scores) that table 9 calcium alimentation composition obtains mouse memory
1.5 conclusion
Experimental result shows, at step down test with keep away in the dark test, tried each experimental group and the wrong reaction prolongation of latency that control group is relatively remembered acquisition that thing gives the calcium alimentation composition of embodiment 1 and embodiment 3, errors number reduction, difference tool conspicuousness; In water maze test, time that each experimental group animal is reached home shortens, and the number of animals of reaching home increases, and errors number reduces, and also has a conspicuousness with the control group comparing difference, and training and cyclical test unanimity as a result.Result of the test shows: the calcium alimentation composition has the function that promotes study and improve memory.
Embodiment 8, calcium alimentation composition food security toxicological test
1. materials and methods
Select ablactation 90 of rats of Wistar (Shenyang Pharmaceutical University zoopery center provides) just for use, between the body weight 80-100g, be divided into 9 groups at random, 10 every group.The experiment contrast group basal feed (Shenyang Pharmaceutical University zoopery center provides) of feeding; 1. experiment is organized, is tested 2. to organize and irritate the calcium alimentation composition that stomach gives the embodiment 1 of 0.4g/kgbw and 1.2g/kgbw respectively on the basal feed basis of feeding; 3. experiment is organized, is tested 4. to organize and irritate the calcium alimentation composition that stomach gives the embodiment 2 of 0.4g/kgbw and 1.2g/kgbw respectively on the basal feed basis of feeding; 5. experiment is organized, is tested 6. to organize and irritate the calcium alimentation composition that stomach gives the embodiment 3 of 0.4g/kgbw and 1.2g/kgbw respectively on the basal feed basis of feeding; 7. experiment is organized, is tested 8. to organize and irritate the calcium alimentation composition that stomach gives the embodiment 4 of 0.4g/kgbw and 1.2g/kgbw respectively on the basal feed basis of feeding; Each group was all fed 60 days continuously.
2. experimental result
Take each experimental group and the control rats of embodiment 1, embodiment 2, embodiment 3, embodiment 4 calcium alimentation compositions and all do not have death; It is all normal that each organizes rat body weight situation, hematology and biochemistry detection, organ weights and histological examination.The result relatively shows: each experimental group and control group no significant difference.Organs and tissues is learned check pathological section and is finished by pathology teaching and research group of Shenyang Pharmaceutical University.
Above-mentioned result of the test shows: calcium alimentation composition avirulence, edible safety.
Scope of the present invention is not subjected to the restriction of described specific embodiments, and described embodiment is only desired also to comprise the method and the component of functional equivalent in the scope of the invention as the single example of illustrating various aspects of the present invention.In fact, except content as herein described, those skilled in the art can easily grasp multiple improvement of the present invention with reference to description above.Described improvement also falls within the scope of appended claims.
Claims (10)
1. an alimentation composition is characterized in that, comprises the active component of following percentage by weight:
Calcium agent 5～94.7%
Vitamin k 0.0001～0.02%
Grease 5～94.7%
Antioxidant 0.001～0.4%
Each percentages of ingredients sum is 100%.
2. alimentation composition according to claim 1 is characterized in that, comprises the active component of following percentage by weight:
Calcium agent 11.8～88%
Vitamin k 0.0002～0.02%
Grease 11.8～88%
Antioxidant 0.006～0.3%
Each percentages of ingredients sum is 100%.
3. alimentation composition according to claim 1 and 2, it is characterized in that described calcium agent is selected from more than one in milk calcium, calcium carbonate, calcium gluconae, amino acid acid chelating calcium, calcium phosphate, calcium chloride, calcium lactate, L-calcium lactate, calcium citrate, citric acid-calcium malate, hydroxyl calcium phosphate, calcium acetate or the l threonic acid.
4. alimentation composition according to claim 1 and 2 is characterized in that, described vitamin k is selected from the derivative of vitamin K1, farnoquinone, farnoquinone or contains the food of described vitamin K.
5. alimentation composition according to claim 4 is characterized in that described vitamin k is selected from MK7.
6. alimentation composition according to claim 1 and 2 is characterized in that, described grease is the grease that is rich in alpha-linolenic acid, be rich in the algal oil of DHA or be rich in the fish oil of DHA.
7. alimentation composition according to claim 1 and 2 is characterized in that, described antioxidant is selected from a kind of in Tea Polyphenols, flavones, ellagic acid, vitamin E, vitamin C, sodium pyrosulfite or the dibutyl hydroxy toluene.
8. alimentation composition preparation comprises each described alimentation composition of claim 1～7 of prevention or treatment effective dose and acceptable carrier pharmaceutically or on the food.
9. alimentation composition preparation according to claim 8, it is characterized in that, described preparation is any oral liquid formulation or solid pharmaceutical preparation, comprises tablet, sugar coated tablet, film coated tablet, enteric coated tablet, capsule, hard capsule, soft capsule, oral liquid, syrup, sucks agent, granule, electuary, pill, powder, paste, sublimed preparation, supensoid agent, solution, suppository, ointment, emplastrum, creme, spray, patch, sustained release preparation or controlled release preparation.
10. each described alimentation composition of claim 1～7 is in preparation prevention or treatment cancer, cardiovascular and cerebrovascular diseases, diabetes, rheumatoid disease, dermatitis disease, depression, schizophrenia, senile dementia, allergy, asthma, ephrosis, aging and chronic plug pneumonia and increase intelligence, strengthen immunity, vision protection, promotion skeleton development or prevent application in the medicine for treating osteoporosis.
Priority Applications (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| CN200910047331A CN101828707A (en) | 2009-03-10 | 2009-03-10 | Nutrition composition and application thereof |
Applications Claiming Priority (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| CN200910047331A CN101828707A (en) | 2009-03-10 | 2009-03-10 | Nutrition composition and application thereof |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| CN101828707A true CN101828707A (en) | 2010-09-15 |
Family
ID=42713047
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| CN200910047331A Pending CN101828707A (en) | 2009-03-10 | 2009-03-10 | Nutrition composition and application thereof |
Country Status (1)
| Country | Link |
|---|---|
| CN (1) | CN101828707A (en) |
Cited By (10)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN102228241A (en) * | 2011-05-27 | 2011-11-02 | 赵锐 | Health-care food capable of tonifying brain, enhancing intelligence and enhancing memory and preparation method thereof |
| CN102626423A (en) * | 2012-04-18 | 2012-08-08 | 广东固升医药科技有限公司 | Compound preparation containing heptaene menadione and application thereof |
| CN103142641A (en) * | 2013-03-11 | 2013-06-12 | 昆明邦宇制药有限公司 | Calcium carbonate-vitamin K pharmaceutical preparation and preparation method thereof |
| CN103202483A (en) * | 2012-01-11 | 2013-07-17 | 浙江康恩贝健康产品有限公司 | Nutritional composition for calcium supplement |
| RU2505290C2 (en) * | 2011-10-31 | 2014-01-27 | Общество С Ограниченной Ответственностью "Консорциум-Пик" | Pharmaceutical composition possessing exhibiting property of endothelial dysfunction reduction accompanying cardiovascular diseases |
| CN108714192A (en) * | 2018-06-22 | 2018-10-30 | 秦皇岛长胜营养健康科技有限公司 | Composition for improving cerebral nerve trophic function and its application |
| CN108851058A (en) * | 2018-07-13 | 2018-11-23 | 德瑞美医药生物技术盐城有限公司 | A kind of multivitamin minerals soft capsule and preparation method thereof rich in alpha-linolenic acid |
| CN110200086A (en) * | 2019-07-03 | 2019-09-06 | 江南大学 | A kind of fat or oil composition |
| CN114766580A (en) * | 2022-03-29 | 2022-07-22 | 四川一只老鹰集团股份有限公司 | Nutritional soft sweet for protecting eyesight health of children and preparation method thereof |
| WO2023178840A1 (en) * | 2022-03-25 | 2023-09-28 | 南京盛德生物科技研究院有限公司 | Pharmaceutical composition for improving life quality of elderly people on basis of vitamin k2, preparation method therefor and use thereof |
-
2009
- 2009-03-10 CN CN200910047331A patent/CN101828707A/en active Pending
Cited By (12)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN102228241A (en) * | 2011-05-27 | 2011-11-02 | 赵锐 | Health-care food capable of tonifying brain, enhancing intelligence and enhancing memory and preparation method thereof |
| RU2505290C2 (en) * | 2011-10-31 | 2014-01-27 | Общество С Ограниченной Ответственностью "Консорциум-Пик" | Pharmaceutical composition possessing exhibiting property of endothelial dysfunction reduction accompanying cardiovascular diseases |
| CN103202483A (en) * | 2012-01-11 | 2013-07-17 | 浙江康恩贝健康产品有限公司 | Nutritional composition for calcium supplement |
| CN102626423A (en) * | 2012-04-18 | 2012-08-08 | 广东固升医药科技有限公司 | Compound preparation containing heptaene menadione and application thereof |
| CN103142641A (en) * | 2013-03-11 | 2013-06-12 | 昆明邦宇制药有限公司 | Calcium carbonate-vitamin K pharmaceutical preparation and preparation method thereof |
| CN103142641B (en) * | 2013-03-11 | 2015-05-20 | 昆明邦宇制药有限公司 | Calcium carbonate-vitamin K pharmaceutical preparation and preparation method thereof |
| CN108714192A (en) * | 2018-06-22 | 2018-10-30 | 秦皇岛长胜营养健康科技有限公司 | Composition for improving cerebral nerve trophic function and its application |
| CN108714192B (en) * | 2018-06-22 | 2021-04-27 | 黄云祥 | Composition for improving brain neurotrophic function and application thereof |
| CN108851058A (en) * | 2018-07-13 | 2018-11-23 | 德瑞美医药生物技术盐城有限公司 | A kind of multivitamin minerals soft capsule and preparation method thereof rich in alpha-linolenic acid |
| CN110200086A (en) * | 2019-07-03 | 2019-09-06 | 江南大学 | A kind of fat or oil composition |
| WO2023178840A1 (en) * | 2022-03-25 | 2023-09-28 | 南京盛德生物科技研究院有限公司 | Pharmaceutical composition for improving life quality of elderly people on basis of vitamin k2, preparation method therefor and use thereof |
| CN114766580A (en) * | 2022-03-29 | 2022-07-22 | 四川一只老鹰集团股份有限公司 | Nutritional soft sweet for protecting eyesight health of children and preparation method thereof |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| CN101828707A (en) | Nutrition composition and application thereof | |
| CN101904507B (en) | Ferrous bisglycinate chelate nutritional composition and application thereof | |
| CN112823648B (en) | Composition, food or medicine and application thereof | |
| CN102038114A (en) | Concentrated feed for barren sows | |
| CN102389055B (en) | Production method of low-cholesterol eggs rich in selenium and zinc | |
| Chang et al. | Nutritional status of preschool children in poor rural areas of China. | |
| CN108741061A (en) | A kind of special diet food and preparation method thereof applied to pregnancy period conditioning | |
| CN101279089B (en) | Donkey-hide gelatin calcium composition and preparing process thereof | |
| Hosnedlová et al. | Current view of the significance of zinc for ruminants: A review | |
| CN106360691A (en) | Selenium-enriched food suitable for people suffering from osteoporosis and preparation method thereof | |
| CN111919889A (en) | Mother-emulsified infant formula goat milk powder capable of improving immunity and preparation method thereof | |
| US20220232876A1 (en) | Composition for use in inducing satiety | |
| Obućinski et al. | Management of blood lipid profile and oxidative status in Holstein and Simmental dairy cows during lactation. | |
| Anderson | Health and nutrition impact of potable water in rural Bolivia | |
| CN103053807B (en) | Water-soluble composite vitamin preparation and preparation method thereof | |
| Kafilzadeh et al. | Effects of feeding dry glycerol on milk production, nutrients digestibility and blood components in primiparous Holstein dairy cows during the early postpartum period | |
| CN111820284A (en) | Infant formula milk powder for optimizing amino acid pattern and improving immunity and preparation method thereof | |
| Milewicz et al. | Intake of iodine-containing multivitamin preparations by pregnant women from the Krakow region of Poland | |
| CN105995119A (en) | High-copper feed for establishing HLD (hepatolenticular degeneration) animal model and preparation method of high-copper feed | |
| Petzold et al. | Feeding conjugated linoleic acids and various concentrate proportions to late pregnant cows and its consequence on blood metabolites of calves | |
| Abdelsalam et al. | Effect of parity on fatty acids of Saudi camels milk and colostrum | |
| Ezzat et al. | Evaluation of adding moringa and rocket seeds oils in the diet on productive and reproductive performance of rabbits under hot climatic conditions | |
| CN114145458A (en) | Application of palmitic acid glyceride in preparing composition for improving or promoting magnesium absorption of human body | |
| Jouanne et al. | Nutrient Requirements during Pregnancy and Lactation. Nutrients. 2021; 13: 692 | |
| Elsherif | Impact of vitamin A supplementation before and during early egg production on laying hen performance |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| C06 | Publication | ||
| PB01 | Publication | ||
| C10 | Entry into substantive examination | ||
| SE01 | Entry into force of request for substantive examination | ||
| ASS | Succession or assignment of patent right |
Owner name: SHANGHAI PIONUO ENTERPRISE MANAGEMENT CO., LTD. Free format text: FORMER OWNER: SHANGHAI PIONUO INDUSTRIAL CO., LTD. Effective date: 20110516 |
|
| C41 | Transfer of patent application or patent right or utility model | ||
| COR | Change of bibliographic data |
Free format text: CORRECT: ADDRESS; FROM: 200032 5/F, NO. 201, ZHAOJIABANG ROAD, XUHUI DISTRICT, SHANGHAI TO: 200023 4/F, RONGKE BUILDING, NO. 443, DAPU ROAD, LUWAN DISTRICT, SHANGHAI |
|
| TA01 | Transfer of patent application right |
Effective date of registration: 20110516 Address after: 200023, Shanghai, Luwan District, Pu Road, No. 443 Rong Branch building, 4 floor Applicant after: Shanghai Pei Bao Kang Enterprise Management Co., Ltd. Address before: 200032, Shanghai, Xuhui District, Jia Bang Road, No. 201, 5 floor Applicant before: Shanghai Bionuo Industrial Stock Co., Ltd. |
|
| C53 | Correction of patent for invention or patent application | ||
| CB02 | Change of applicant information |
Address after: 201799, No. 69, 2 floor, 3 floor, 202 Huafang Road, Qingpu District, Shanghai, Applicant after: Sinopharm Nutraceuticals (Shanghai) Co., Ltd. Address before: 200023, Shanghai, Luwan District, Pu Road, No. 443 Rong Branch building, 4 floor Applicant before: Shanghai Pei Bao Kang Enterprise Management Co., Ltd. |
|
| COR | Change of bibliographic data |
Free format text: CORRECT: APPLICANT; FROM: SHANGHAI PIONUO ENTERPRISE MANAGEMENT CO., LTD. TO: SINOPHARM NUTRACETICALS (SHANGHAI) CO., LTD. |
|
| C02 | Deemed withdrawal of patent application after publication (patent law 2001) | ||
| WD01 | Invention patent application deemed withdrawn after publication |
Application publication date: 20100915 |